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Abstract
Introduction: Nomograms are statistical tools designed to predict outcomes. This study evaluates the
effects of peri-operative chemotherapy on the accuracy of a prognostic nomogram for disease-specific
survival (DSS) after resection of colorectal liver metastases (CRLM) established at Memorial-Sloan
Kettering Cancer Center (MSKCC).hpb_106 592..599
Methods: An external cohort of 203 patients who underwent resection of CRLM between 1996 and 2006
was used to assess the nomogram.
Results: After median follow-up of 30.4 months (range 0.33–150), Kaplan–Meier (KM) estimates for 3-,
5- and 8-year post-resection DSS were 56%, 41%, and 32%, respectively; similar to nomogram-
predicted probabilities for DSS. The concordance index for the nomogram was higher (0.602) than for the
Fong colorectal risk score (CRS; 0.533). KM DSS was longer for patients (n = 50) treated with at least 6
months of peri-operative irinotecan or oxaliplatin compared with all other patients (median 66 vs. 40
months, P = 0.06). KM DSS was greater than nomogram predicted DSS for treated patients and less than
nomogram predicted DSS for all other patients.
Conclusions: The CRLM nomogram was validated by an external cohort and more accurately predicted
post-resection survival than the commonly used CRS. Differences in observed and nomogram-predicted
survival may reflect the effect of treatment factors, such as peri-operative chemotherapy.
Keywords
colorectal liver metastases, nomogram, chemotherapy
Received 25 March 2009; accepted 16 June 2009
Correspondence
Rebekah R. White, 489 Seeley G. Mudd Building, Durham, NC 27710, USA. Tel: 1 919 684 6553; Fax:
1 919 681 7508; E-mail: rebekah.white@duke.edu
Introduction
Several institutions have developed prognostic scoring systems
for survival after surgical extirpation of colorectal liver
metastases (CRLM) incorporating patient demographics, clini-
copathologic tumour characteristics and extent of hepatic
resection.1–9 However, the validity of these scoring classifications
when applied to external data cohorts has been inconsistent as
heterogeneous survival outcomes among patients with similar
risk scores have been observed.10–15 For example, some centres
have noted significant long-term survival rates after partial hepa-
tectomy among patients with poor predictive risk scores.16 In an
effort to improve on these scoring systems, two groups have
independently designed prognostic nomograms for survival after
resection of CRLM from large hepatic resection databases.17,18
Nomograms are statistical tools that provide probability of a
particular outcome and have been developed to predict survival
for pancreatic, lung, hepatocellular, prostate, renal cell and
oesophageal cancers.19–24 In comparison to traditional scoring
systems, advantages of prognostic nomograms include the ability
to accurately account for continuous variables [such as number
and size of CRLM, carcino-embyronic antigen (CEA) level and
disease-free interval from resection of the primary tumour to
diagnosis of CRLM] by taking the specific value for these factors
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into consideration and the ability to allocate greater influence to
particular factors in predicting survival after resection. Despite
survival benefits of chemotherapy for resectable CRLM observed
in prospective randomized controlled trials and large retrospec-
tive case series,25–29 neither prognostic nomogram for survival
after resection of CRLM account for chemotherapy treatment.
The Memorial Sloan-Kettering Cancer Center (MSKCC) nomo-
gram in particular was constructed using an internal population
of patients who underwent resection of CRLM from October
1985 to October 1998 – before the widespread use of contem-
porary chemotherapeutics including oxaliplatin and irinotecan.17
While this nomogram has been validated by an internal cohort,17
external validation of this cohort has not yet been demonstrated.
External validation is essential to account for institution-
specific factors that may bias results, including particular
selection criteria for resection, surgical approaches or patient
characteristics. The objectives of this study were to (i) assess the
accuracy of the MSKCC nomogram (Fig. 1) for predicting
96-month disease-specific survival (DSS) relative to the
Blumgart-Fong colorectal risk score (CRS)1 on an external
patient cohort; and (ii) evaluate the effects of peri-operative
irinotecan or oxaliplatin treatment on the predictive accuracy of
the MSKCC nomogram.
Methods
After obtaining approval from the Duke University Medical
Center (DUMC) Institutional Review Board for Clinical Investi-
gations, patient demographics, clinicopathologic tumour charac-
teristics, treatments and survival outcomes for patients who
underwent resection of CRLM were reviewed from a retrospec-
tively collected database. From 1996–2006, 289 patients under-
went resection of CRLM. Patients who suffered mortality within
90 days of hepatic resection (n = 10), had gross disease at any
location after partial hepatectomy (n = 32), had extra-hepatic
metastatic disease at partial hepatectomy (n = 17) and who under-
went previous hepatic resection (n = 26) were excluded. These
exclusion criteria are similar to those used for creation of the
MSKCC nomogram. One patient with both CRLM and hepato-
cellular carcinoma on pathological examination was also
excluded. The 203 remaining patients formed the DUMC external
cohort used to validate the MSKCC nomogram. There were no
Figure 1 Memorial-Sloan Kettering
Cancer Center (MSKCC) prognostic
nomogram for predicting 96-month
disease-specific survival (DSS) after
resection of colorectal liver metastases
(CRLM). Reproduced with permission
from Kattan et al.17
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uniform criteria for administration of chemotherapy before or
after partial hepatectomy. The specific drug combination used for
each patient was at the discretion of the treating medical oncolo-
gist. Thus, no particular regimen was selected as first-line therapy.
Fluoropyrimidine monotherapy (modalities of treatment
included intravenous, oral, or via hepatic arterial infusion) with or
without leucovorin was used before 2000. From 2000–2006, com-
binations of oxaliplatin or irinotecan-based chemotherapy with
or without the anti-biologic agents bevacizumab or cetuximab
were preferentially utilized, when tolerated. Pre-resection chemo-
therapy included treatment after discovery of CRLM and before
hepatic resection. Post-resection chemotherapy consisted of treat-
ment after partial hepatectomy and before disease recurrence.
Peri-operative chemotherapy included treatment before and/or
after hepatic resection. Duration of chemotherapy treatment was
calculated from the date of initial to final dose of treatment.
Discrete and continuous variables were compared with the c2-
or Fisher’s exact tests and the Wilcoxon rank test, respectively.
Disease-specific survival (DSS) was calculated using date of death
because of disease or date of last follow-up. DSS was estimated
using the Kaplan–Meier method. Nomogram validation com-
prised two activities. First, discrimination was quantified with the
concordance index which provides the probability that, in a ran-
domly selected pair of patients in which one patient dies of disease
before the other, the patient who died first had the worse predicted
outcome from the nomogram. Bootstrapping was used to assess
the magnitude of the difference in the predictive accuracy between
the nomogram and the Fong colorectal risk score. Second, cali-
bration was assessed by grouping patients by nomgram-predicted
probabilities and then comparing the mean nomogram predicted
survival of the group with the observed Kaplan–Meier estimate of
DSS. All analyses were performed using S-plus 2000 Professional
Software (Statistical Sciences, Seattle, WA, USA) or R version
2.8.1(http://www.R-project.org) with the Design and Hmisc
libraries added.
Results
While there were similarities in gender, rectal primary tumours
and primary lymph node staging, there were several differences in
tumour characteristics between the patient cohorts (Table 1).
Compared with the MSKCC cohort, DUMC patients had lower
Table 1 Demographics, clinicopathologic tumour characteristics and treatments for the patients in the Duke University Medical Center
(DUMC) and Memorial-Sloan Kettering Cancer Center (MSKCC) cohorts are compared. Continuous variables are listed as medians with 1st
and 3rd quartiles, discrete variables are listed with percentages
Variables MSKCC DUMC P
n 1475 203 –
Gender 0.770
Male 853 (57.8%) 120 (59.1%)
Female 624 (42.2%) 83 (40.9%)
Primary tumour 0.281
Colon 1092 (74.0%) 158 (77.8%)
Rectum 383 (26.0%) 45 (22.2%)
Primary lymph node 0.1373
0 564 (40.1%) 66 (34.7%)
1 588 (41.8%) 79 (41.6%)
2 255 (18.1%) 45 (23.7%)
Pre-operative CEA (ng/ml) 16.4 (5.7, 64.3) 8.9 (2.9, 30.1) <0.0001
Number of CRLM 2 (1, 3) 1 (1, 2) 0.0016
Size of largest CRLM (cm) 4.1 (2.8, 6.4) 3.4 (2.2, 5.5) 0.0002
Age (year) 62.8 (54.2, 69.6) 61.0 (51.8, 68.8) 0.06
Disease-free interval (mo) 14.4 (4.4,26) 2 (0, 16) <0.0001
Bilateral resection
No 890 (60.3%) 150 (73.9%) 0.0002
Yes 587 (39.7%) 53 (26.1%)
>1 Lobe resected
No 528 (35.7%) 133 (65.5%) <0.0001
Yes 949 (64.3%) 70 (34.5%)
CRLM, colorectal liver metastases; CEA, carcino-embyronic antigen.
Disease-free interval refers to interval from resection of the primary tumour to diagnosis of CRLM.
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pre-resection CEA levels, fewer and smaller CRLM and tended to
be younger at hepatic resection. DUMC patients had a shorter
disease-free interval from resection of primary tumour to diag-
nosis of CRLM and less often underwent bilateral and greater than
one lobe of hepatic resection. The MSKCC nomogram was
validated with the DUMC external patient cohort (Fig. 2). After a
median follow-up of 30.2 months, Kaplan–Meier (KM) estimates
for 3-, 5- and 8-year post-resection DSS were 56%, 41%, and 32%,
similar to nomogram predicted probabilities for DSS (Fig. 3). The
estimated KM survival outcomes were similar to that of other
large series of partial hepatectomy for colorectal metastases.30–32
The nomogram concordance index was higher than the concor-
dance index for the CRS (0.602 vs. 0.533, P = 0.04). Nomogram
predicted survival probabilities were heterogeneous within CRS
scores, particularly for the lower scores (Fig. 4).
We focused on those patients treated with at least 6 months of
peri-operative irinotecan or oxaliplatin relative to hepatic resec-
tion as 6 months was the intended duration of FOLFOX4 chemo-
therapy among the treatment group in the EORTC 40983
randomized controlled trial.22 Fifty out of 203 (24.6%) patients
were treated with peri-operative irinotecan or oxaliplatin-based
chemotherapy for a total of at least 6 months. Twenty-four (48%)
of these patients were treated with irinotecan, 21 (42%) were
treated with oxaliplatin and 5 patients (10%) were treated with
both irinotecan and oxaliplatin. Many patients were treated before
the widespread use of these agents. Patients were treated by a
variety of medical oncologists both inside and outside our insti-
tution, and there was no established ‘standard of care’. Seventeen
patients (34%) were treated with pre-resection chemotherapy
only, 10 (20%) were treated with post-resection chemotherapy
only, and 33 (66%) patients were treated with both pre-resection
and post-resection chemotherapy. Forty-nine out of 203 patients
(24.1%) were treated with peri-operative irinotecan or oxaliplatin
for a total of less than 6 months (median treatment duration of
three months). Fifty-five out of 203 (27.1%) patients were treated
with alternate chemotherapy (most commonly 5-fluorouracil)
and 49/203 (24.1%) were treated with no chemotherapy before or
after partial hepatectomy. Patients with a follow-up after resection
of less than 6 months were excluded from subsequent analyses.
Nomogram predicted post-resection DSS was compared with
observed DSS for the 50 patients treated with at least 6 months of
peri-operative irinotecan or oxaliplatin and the 153 remaining
patients (Fig. 5). Observed DSS was greater than nomogram pre-
dicted DSS for the 50 patients treated with at least 6 months of
peri-operative irinotecan or oxaliplatin at 1, 2 and 3 years after
hepatic resection, and less than nomogram predicted DSS for all
other patients. A landmark analysis was performed to evaluate the
independent effect of duration of peri-operative chemotherapy
on DSS. Length of post-resection treatment was truncated at 6
months. Maximal survival benefit from peri-operative irinotecan
or oxaliplatin was observed with a duration of 6 months of che-
motherapy, although the effect of chemotherapy was not statisti-
cally significant (Fig. 6).
Discussion
Enhancements in surgical technique, pre-operative imaging, criti-
cal care and understanding of hepatic anatomy have dramatically
improved survival after resection of CRLM. Despite these
improvements, long-term survival after resection of CRLM is not
uniform as recent large case series note 5-year survival of
40–50%.7,27,29,33 In an attempt to better predict prognosis after
partial hepatectomy, Kattan et al.17 have designed a prognostic
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Figure 2 Duke University Medical Center (DUMC) cohort calibration
curve – observed disease-specific survival (DSS) versus nomogram
predicted DSS. DUMC patients were stratified into three groups
based on nomogram predicted DSS – vertical lines with error bars
depict the performance of the Memorial-Sloan Kettering Cancer
Center (MSKCC) nomogram applied to DUMC patients. The ideal
nomogram is depicted by the diagonal line
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Figure 3 Observed Kaplan–Meier (KM) disease-specific survival
(DSS) vs. Memorial-Sloan Kettering Cancer Center (MSKCC) nomo-
gram predicted DSS after resection of colorectal liver metastases
(CRLM) for the Duke University Medical Center (DUMC) patient
cohort
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Figure 4 Comparisons of nomogram
predicted probabilities of disease-
specific survival (DSS) by CRS risk
score. Note the heterogeneity for pre-
dicted survivals within each colorectal
risk score (CRS) score
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Figure 5 Observed disease-specific survival (DSS) at 1, 2 and 3
years after hepatic resection versus mean nomogram predicted DSS
stratified by peri-operative chemotherapy treatment for patients with
follow-up after liver resection of at least 6 months. The 48 patients
treated with peri-operative irinotecan or oxaliplatin are compared
with the other 144 patients. The lines with error bars represent the
performance of the Memorial-Sloan Kettering Cancer Center
(MSKCC) nomogram applied to the Duke University Medical Center
(DUMC) patients. The diagonal line represents the performance of an
ideal nomogram
0
–0.5
0.0
0.5
2
lo
g 
Re
la
tiv
e 
Ha
za
rd
4
Total length of iri/oxal chemotherapy (Months)
6 8 10 12
Figure 6 Landmark analysis for hazard ratio for disease-specific sur-
vival (DSS) by peri-operative irinotecan or oxaliplatin (iri/oxal)
therapy. Post-resection chemotherapy was truncated at 6 months
and all patients with follow-up time less than 6 months were
excluded form this landmark analysis. The total length of iri/oxal
chemotherapy was recalculated as the sum of the pre-resection
chemotherapy and truncated post-resection chemotherapy. P = 0.27
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nomogram incorporating patient demographic and clinicopatho-
logic variables. Our report describes the validation of this nomo-
gram by an external cohort (Fig. 2) despite several differences in
clinicopathologic tumour characteristics between the DUMC and
MSKCC patient cohorts (Table 1). The MSKCC nomogram
concordance index when applied to the DUMC cohort was 0.602,
slightly lower than the internal validation concordance index of
0.688.17 This implies that for any two randomly selected patients
in the DUMC cohort, there is roughly a 60% chance that the
MSKCC nomogram predicts the patient with shorter DSS. While
superior to the CRS (which had a concordance index only slightly
better than chance), there is substantial room for improvement.
There are three potential stages in the overall treatment of
patients with CRLM where nomograms may affect clinical deci-
sions: (i) to determine whether resection or chemotherapy
should be the initial treatment; (ii) after pre-resection chemo-
therapy to determine if surgical extirpation should be performed;
and (iii) after partial hepatectomy to determine administration
of post-resection chemotherapy and ultimate prognosis. As
noted by Kanemitsu and Kato,18 different factors affect decision
making at each stage. Upon initial diagnosis of CRLM, therapeu-
tic decisions are governed by patient demographics, comorbidity
and clinicopathological tumor characteristics identified on pre-
operative imaging or prior colorectal resection. Response to pre-
resection chemotherapy also determines subsequent operative
interventions as some studies have shown that patients with
unresponsive or progressive disease after pre-resection chemo-
therapy treatment have poorer survival after hepatic resection
compared with patients with responsive disease.34–36 After surgi-
cal extirpation, additional treatment factors (such as extent of
resection and width of hepatic resection margins) may also influ-
ence the use of post-resection chemotherapy and ultimate prog-
nosis. While useful as a tool for counselling patients regarding
prognosis, further modifications to the nomogram – or perhaps
creation of specific nomograms for different stages of treatment
– are necessary to reach a level of predictive accuracy sufficient
for making treatment decisions for individual patients. Addi-
tional factors noted above that have been shown to alter selection
criteria for resection or are associated with survival after partial
hepatectomy could be incorporated to improve nomogram pre-
dictive accuracy. These include positron emission tomography
(PET),37–42 width of hepatic resection margin,33–46 and response to
pre-operative chemotherapy treatment.34–36 In addition, molecu-
lar predictors of prognosis and response are actively being sought
by many groups.
The EORTC 40983 randomized controlled trial demonstrated
benefits in progression-free survival among patients treated with
peri-operative FOLFOX4 compared with patients treated with
partial hepatectomy alone among patients who ultimately were
resected [42.4% (34.0–50.5%) vs. 33.2% (25.3–41.2%), P =
0.025].25 These results have been used by many to support the use
of peri-operative chemotherapy for CRLM. Thus, this study was
designed to evaluate the effects of similar durations of peri-
operative irinotecan or oxaliplatin treatment on the predictive
accuracy of the MSKCC nomogram.
In this study, observed Kaplan–Meier survival for patients
treated with at least 6 months of peri-operative irinotecan or
oxaliplatin in the DUMC cohort at 1, 2 and 3 years after resec-
tion was greater than the corresponding nomogram predicted
survival whereas corresponding observed survival for all other
patients was less than nomogram predicted survival (Fig. 5).
Treatment with at least 6 months of peri-operative irinotecan or
oxaliplain chemotherapy did not have a statistically significant
effect on survival, but more than one-half of the other patients
were treated with some type of chemotherapy, which may lead
to underestimation of the effect of modern chemotherapy.
These analyses do not address the relative value of preoperative
versus post-operative chemotherapy but do suggest that
differences in observed and nomogram predicted survival
rates, which are based purely on demographical and clinico-
pathological criteria, may be attributable to contemporary
chemotherapeutics.
There are several limitations to this retrospective study. The
administration of pre-resection and/or post-resection chemo-
therapy and the specific drug regimens and dosing schedules were
all at the discretion of the treating medical oncologists. In our
study, the relatively small number of patients who were treated
with at least 6 months of irinotecan or oxaliplatin, the subsequent
heterogeneity in chemotherapy regimens and durations of treat-
ment and probable biases in selecting patients for chemotherapy
treatment (particularly pre-resection chemotherapy) prevent us
from making definitive statements concerning the benefits of che-
motherapy for CRLM based on this study alone. For example,
patients who suffered major complications after hepatic resection,
with overall poor performance status or with severe adverse reac-
tions to chemotherapy were likely not to be treated with extended
durations of oxaliplatin or irinotecan before or after partial hepa-
tectomy. Thus, it is possible that some of the difference in KM
observed and nomogram predicted survival for patients treated
with at least 6 months of peri-operative irinotecan or oxaliplatin
was as a result of selection bias as opposed to efficacy of chemo-
therapy treatment. We were also unable to evaluate the specific
effects of biological agents as these agents were not uniformly
utilized. Another limitation of this study is that some of the clini-
copathological data utilized for application to the MSKCC nomo-
gram were based on post-operative pathological examination.
Pre-operative treatment may affect certain factors in the nomo-
gram (e.g. maximum tumor size) and may therefore affect
nomogram-predicted survival, obscuring a treatment effect in our
analysis.
In conclusion, the MSKCC nomogram for DSS after resection
of CRLM was validated by an external cohort and more accurately
predicted survival than the commonly used CRS. Further refine-
ments to the nomogram will likely improve its predictive accuracy
in individual patients. Meanwhile, comparisons of observed to
nomogram-predicted survival rates in groups of patients may be
HPB 597
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useful for the evaluation of treatment factors not incorporated
into the nomogram.
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